384 related articles for article (PubMed ID: 37506033)
1. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W; Huang G; Cui W; Tian Y; Sun Q; Zhao X; Zhao Y; Li D; Liu X
Int Braz J Urol; 2023; 49(5):535-563. PubMed ID: 37506033
[TBL] [Abstract][Full Text] [Related]
2. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
[TBL] [Abstract][Full Text] [Related]
5. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.
Mostafaei H; Salehi-Pourmehr H; Jilch S; Carlin GL; Mori K; Quhal F; Pradere B; Grossmann NC; Laukhtina E; Schuettfort VM; Aydh A; Sari Motlagh R; König F; Roehrborn CG; Katayama S; Rajwa P; Hajebrahimi S; Shariat SF
Eur Urol Focus; 2022 Jul; 8(4):1072-1089. PubMed ID: 34563481
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of Therapeutic Efficacy and Safety of Solifenacin versus Tolterodine in Patients with Overactive Bladder: A Meta-Analysis.
Wang HT; Xia M
Urol Int; 2019; 103(2):187-194. PubMed ID: 31170710
[TBL] [Abstract][Full Text] [Related]
7. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
[TBL] [Abstract][Full Text] [Related]
10. Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial.
Newgreen D; Bosman B; Hollestein-Havelaar A; Dahler E; Besuyen R; Sawyer W; Bolduc S; Rittig S
Eur Urol; 2017 Mar; 71(3):483-490. PubMed ID: 27687820
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
12. [Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes].
Liu B; Li P; Li J; Wang Y; Wu Y
Zhonghua Yi Xue Za Zhi; 2014 Aug; 94(30):2350-4. PubMed ID: 25399976
[TBL] [Abstract][Full Text] [Related]
13. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
J Urol; 2021 May; 205(5):1421-1429. PubMed ID: 33356445
[TBL] [Abstract][Full Text] [Related]
14. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.
He W; Zhang Y; Huang G; Tian Y; Sun Q; Liu X
Low Urin Tract Symptoms; 2023 May; 15(3):80-88. PubMed ID: 36863312
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis.
Yang N; Wu Q; Xu F; Zhang X
J Int Med Res; 2021 Sep; 49(9):3000605211042994. PubMed ID: 34510960
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.
Sebastianelli A; Russo GI; Kaplan SA; McVary KT; Moncada I; Gravas S; Chapple C; Morgia G; Serni S; Gacci M
Int J Urol; 2018 Mar; 25(3):196-205. PubMed ID: 29205506
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]